跳到正文
原文
Endpoints News 生物医药· Ayisha Sharma·· 2026-10-15AI 评分44

Vanda 社交焦虑症药物 VQW-765 三期试验在女性患者中失败

Vanda’s social anxiety drug flunks Phase 3 trial in female patients

AI 导读

Vanda Pharmaceuticals 宣布,由于一项晚期试验在女性患者中未达终点,暂停其社交焦虑症药物 VQW-765 的研发项目。

正文

Van­da Phar­ma­ceu­ti­cals said Wednes­day it is putting its so­cial anx­i­ety dis­or­der pro­gram on hold fol­low­ing a late-stage tri­al fail­ure.

The biotech’s drug, called VQW-765,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news